Protalix Ltd.

Hadasit Medical Research Services and Development Ltd.

Compugen Ltd. Corporation

Yoseph Shaaltiel

Tali Kizhner

Avidor Shulman

Gideon Baum

Ilya Ruderfer

Daniel Bartfeld

Sharon Hashmueli

Uri Hanania

Ayala Lewkowicz

Yaniv Azulay

Talia Shekhter

Tehila Ben-Moshe

Liat Fux

Svetlana Gingis-Velitski

Tami Ariel

Yulia Matiuhin

Lilach Chen Zeltsburg

Yulia Ugortsev

Elad Lavee Laviad

Sivan Gelley

Hagit Neta

Yaron Ilan

Dvir Dahary

Ronen Shemesh

Einat Almon

Jeanne Bernstein

Myriam Golembo

Sari Alon

Raul Chertkoff

Gil Shalev

Yehava Forester

Einat Mizrachi

Yair Kirshner

Alon Shtainiz

Yaron Naos

Yftach Shneor

Tehila Ben Moshe

Tal Ratz

Orit Shilovittzky

Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Stabilized alpha-galactosidase and uses thereof

Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and unit dosages of protein are disclosed herein. The disclosed protocols are safe, have greater than 2 week intervals between administrations and exhibit important improvement in patient's disease parameters, in terms of reduced Gb3 accumulation, pain and GI parameters, kidney and cardiac stabilization in the clinical setting.

Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

Modified DNase and uses thereof

A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising:

Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

A reusable, disposable device for culturing plant tissues or cells including a non-rigid container having dimensions and gas exchange ports designed for maintaining oxygen saturation and shear forces suitable for culturing plant tissue or cells in 400 liters or more of culture medium is provided. Also provided are methods for producing a catalytically active human recombinant protein in a plant cell, using the disposable device of one of the embodiments of the instant specification.

Large scale disposable bioreactor

Stabilized &#x3b1;-galactosidase and uses thereof

A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.

Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.

Nucleic acid expression constructs are provided and, more particularly, nucleic acid constructs for expression of human alpha-galactosidase in plant cells, cells expressing the nucleic acid construct, producing the human alpha-galactosidase and uses thereof.

Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.

Dry powder formulations of dNase I

An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.

Inhalable liquid formulations of DNase I

A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

Plant cell culture expressing human lysosomal proteins and uses thereof

Growing community of inventors

Timrat, Israel

Yoseph Shaaltiel